Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer
- PMID: 21760602
- DOI: 10.1038/ki.2011.133
Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer
Abstract
Erythropoiesis-stimulating agents (ESAs) have been used for about three decades in chronic kidney disease patients to treat the symptoms of anemia, avoid potentially hazardous blood-product transfusions, improve some facets of quality of life, and reduce cardiovascular risk. We review a new article in which this association between stroke and ESA use is examined in a different population in a different way, but with the same worrying findings as seen in the TREAT study.
Comment on
-
Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease.Kidney Int. 2011 Aug;80(3):288-94. doi: 10.1038/ki.2011.49. Epub 2011 Mar 9. Kidney Int. 2011. PMID: 21389972 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
